MedDRA preferred term

Thrombotic microangiopathy: adverse event reports recording this term

9,551 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

9,551
reports recording the term: 0.1% of all reports; 867
reports, 12 months to June 2026: 764 in the 12 months before; 99.7%
marked serious by the reporter: 57.4% across all reports; 19.7%
record death among outcomes, as reported: 9.1% across all reports

9,551 reports in FDA's adverse event database record the MedDRA term "Thrombotic microangiopathy": 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

867 reports recorded it in the 12 months to June 2026, up 13% from 764 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 99.7% are marked serious, 19.7% include death among the outcomes and 46.7% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Tacrolimus, Mycophenolate mofetil and Cyclosporine. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Tacrolimus	Calcineurin inhibitor immunosuppressant	2,185	2.3%
Mycophenolate mofetil	Antimetabolite immunosuppressant	946	1.2%
Cyclosporine	Calcineurin inhibitor immunosuppressant	739	1.9%
Gemcitabine	Nucleoside metabolic inhibitor	678	2%
Cyclophosphamide	Alkylating drug	655	0.5%
Soliris	Complement inhibitor	644	1.2%
Methotrexate	Folate analog metabolic inhibitor	446	0.2%
Prograf	Calcineurin inhibitor immunosuppressant	423	2.1%
Fludarabine	Nucleoside metabolic inhibitor	386	1.9%
Prednisolone	Corticosteroid	382	0.4%
Methylprednisolone	Corticosteroid	368	0.7%
Prednisone	Corticosteroid	356	0.2%
Melphalan	Alkylating drug	330	1.9%
Dexamethasone	Corticosteroid	320	0.2%
Bevacizumab	Vascular endothelial growth factor inhibitor	315	0.6%
Sirolimus	Kinase inhibitor	315	3.2%
Carboplatin	Platinum-based drug	312	0.3%
Etoposide	Topoisomerase inhibitor	294	0.5%
Busulfan	Alkylating drug	283	2.4%
Rituximab	CD20-directed cytolytic antibody	278	0.2%
Carfilzomib	Proteasome inhibitor	257	2.2%
Gemcitabine hydrochloride	Nucleoside metabolic inhibitor	252	2%
Thiotepa	Alkylating drug	238	3%
Basiliximab	Interleukin-2 receptor blocking antibody	193	2.8%
Everolimus	Kinase inhibitor	184	1.3%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Calcineurin inhibitor immunosuppressant	3,533	1.7%	0.8%
Nucleoside metabolic inhibitor	1,724	0.6%	0.1%
Alkylating drug	1,592	0.6%	0%
Corticosteroid	1,592	0.2%	0%
Antimetabolite immunosuppressant	1,249	1%	0.9%
Complement inhibitor	783	1.1%	0.4%
Kinase inhibitor	767	0.1%	0%
Proteasome inhibitor	596	0.5%	0.3%
Platinum-based drug	584	0.3%	0.2%
Folate analog metabolic inhibitor	544	0.2%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 22.5%242

2 to 115.4%512

12 to 173.3%312

18 to 4420.3%1,941

45 to 6430.4%2,906

65 to 7413.4%1,284

75 and over4.7%448

Age not given20%1,906

Patient sex

Female44.3%4,231

Male40.4%3,859

Not given15.3%1,461

Grey bar: all 20,646,523 reports in the database. 31% of these reports give the United States as the country.

Questions about "Thrombotic microangiopathy"

What does "Thrombotic microangiopathy" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record thrombotic microangiopathy?

9,551 reports through June 2026 (0.1% of all reports), 867 of them in the latest 12 months.

Which drugs appear most often in these reports?

Tacrolimus (2,185), Mycophenolate mofetil (946), Cyclosporine (739), Gemcitabine (678) and Cyclophosphamide (655). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.